Context Therapeutics Inc. (CNTX)

NCM – Real Time Price. Currency in USD

0.47

+0.00 (0.94%)

Market open: Aug 12, 2026, 3:44 PM EDT

0.47

+0.01 (1.65%)

Previous after-hours: Aug 11, 2026, 7:45 PM EDT

05.08.2026

Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress

Prioritization of CTIM-76 and CT-202 clinical programs, with initial clinical readouts expected beginning in Q2 2027 Cash and cash equivalents of $43.0 million as of June 30, 2026 expected to fund operations into Q4 2027 PHILADELPHIA, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced its financial results for the second quarter ended June 30, 2026, and reported on recent and upcoming business highlights. “During the second quarter, we advanced our pipeline and reported interim Phase 1a data from CTIM-76 in a limited number of heavily pretreated patients with platinum-resistant ovarian cancer (“PROC”) receiving weekly dosing,” said Martin Lehr, Chief Executive Officer of Context.

Videos

No Data

There is no data to display

Press releases

05.08.2026

Context Therapeutics Inc. (CNTX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Context Therapeutics Inc. (CNTX)

Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress

Videos

No Data

Press releases

Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress

Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress

Videos

No Data

Press releases

Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress

Search stocks

Context Therapeutics Inc. (CNTX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Context Therapeutics Inc. (CNTX)

Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress

Videos

No Data

Press releases

Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress

Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress

Videos

No Data

Press releases

Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress